Head-to-head evidence
CM512 vs JNJ-95597528
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: TSLP + IL-13 · full Atopic Dermatitis pipeline
CM512
Developed by Keymed Biosciences
NCT06553209 · Phase 1 · completed
The study randomly assigned participants to active drug or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. However, its only defined goal was tracking adverse events rather than any measure of skin-disease improvement. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT07230483 (registry estimate)
JNJ-95597528
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT07230860 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CM512's landscape · JNJ-95597528's landscape